Targeting cyclin-dependent kinase 4 and 6 (CDK4/6), the proteins controlling cell cycle entry, has become an attractive tumor treatment strategy for RB Transcriptional Corepressor 1 (RB1) wild-type patients2,3. Here, RB1 is linked to neoplasm.